ACUTE TOXICITY STUDY OF (Z)-1-BENZHYDRYL-4- CINNAMYLPIPERAZINES IN SWISS ALBINO MICE
Objective: The objective was to study the acute toxicity of (Z)-1-benzhydryl-4-cinnamylpiperazine derivatives (1a-c) using Swiss Albino mice.
Methods: The acute oral and dermal toxicity studies were carried out based on OECD guidelines by adopting fixed dosage method (the limit dose
is 2000 mg/kg body weight of test animal in case of dermal toxicity and 5000 mg/kg in oral toxicity). Toxicity and mortality rates were studied at
intervals of 6 hrs and 14 hrs after administration of test compounds for 14 days.
Results: (Z)-1-benzhydryl-4-cinnamyl piperazine derivatives (1a-c) at oral treatment of 5000 mg/kg BW and dermal toxicity study of 2000 mg/kg
BW did not show any pronounced toxicity indicating their potential use for therapeutic purposes.
Conclusion: All compounds 1a-c did not cause any mortality or changes in general behavior of the test animals at oral treatment of 5000 mg/kg BW
indicating no conspicuous toxicity at the highest dose administered.
Keywords: (Z)-1-benzhydryl-4-cinnamyl piperazine derivatives, Acute toxicity, Albino mice, Cinnarizine, Flunarizine.
2. Lee JA, Watson LA, Boothby G. Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med 1986;57(1):45-8.
3. Verspeelt J, De Locht P, Amery WK. Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. Eur J Clin Pharmacol 1996;51(1):15-22.
4. Rascol O, Clanet M, Montastruc JL. Calcium antagonists and the vestibular system: A critical review of flunarizine as an antivertigo drug. Fundam Clin Pharmacol 1989;3 Suppl:79S-87.
5. Mena MA, Garcia de YÃ©benes MJ, Tabernero C, Casarejos MJ, Pardo B, Garcia de YÃ©benes J. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995;18(5):410-26.
6. Micheli FE, Pardal MM, Giannaula R, Gatto M, Parera I, Paradiso G, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 1989;4(2):139-46.
7. Lucertini M, Mirante N, Casagrande M, Trivelloni P, Lugli V. The effect of cinnarizine and cocculus indicus on simulator sickness. Physiol Behav 2007;91(1):180-90.
8. Van Nueten JM, Janssen PA. Comparative study of the effects of flunarizine and cinnarizine on smooth muscles and cardiac tissues. Arch Int Pharmacodyn Ther 1973;204(1):37-55.
9. Barber JH, Reuter CA, Jageneau AH, Loots W. Intermittent claudication: A controlled study in parallel time of the short-term and long-term effects of cinnarizine. Pharmatherapeutica 1980;2(6):401-7.
10. Desmedt LK, Niemegeers CJ, Janssen PA. Anticonvulsive properties of cinnarizine and flunarizine in rats and mice. Arzneimittelforschung 1975;25(9):1408-13.
11. Schetz J, Bostoen H, Clement D, Fornhoff M, Haerens AR, Staessen AI. Flunarizine in chronic obstructive peripheral arterial disease. A placebo-controlled, double-blind, randomized multicentre trial. Curr Ther Res Clin Exp 1978;23:121-30.
12. Jan M, Paul MV. Flunarizine. In: Scriabine A, editor. New Drugs Annual: Cardiovascular Drugs. Vol. 2. New York: Raven Press; 1984.
13. Shivaprakash S, Burman A, Dewakar L, Reddy GC. In vivo studies of (Z)-1-benzhydryl-4- cinnamylpiperazines as anti-inflammatory and analgesics. Int J Pharm 2014;4(3):154-7.
14. Shivaprakash S, Reddy GC. Stereoselective synthesis of (Z)-1-benzhydryl-4- cinnamylpiperazines via the Wittig reaction. Synth Commun 2014;44:600-9.
15. OECD Guidelines for the Testing of Chemicals (No. 423) Acute Oral Toxicity-Acute Toxic Class Method [Adopted on 2011 Dec 17]. (b) OECD Guidelines for the Testing of Chemicals (No. 402) Acute Dermal Toxicity-Acute Toxic Class Method [Adopted on 2004 May 14]. (1st Version).
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.